Dacomitinib/Dacomitinib was developed and produced by which country?

Dacomitinib/Dacomitinib (Dacomitinib) is a second-generation EGFR tyrosine kinase inhibitor developed by Pfizer Inc., specifically used to treat non-small cell lung cancer patients with EGFR sensitive mutations. Pfizer, as the world's leading multinational pharmaceutical company, has profound capabilities in the research and development of molecularly targeted drugs. Dacomitinib is a representative result developed on its "pan-HER target" research platform. This drug was initially used for early drug screening and mechanism verification in the United States, and then a global multi-center clinical study was conducted to evaluate its effectiveness and safety in the treatment of lung cancer.

After several years of development and review, dacomitinib was finally approved by the U.S. Food and Drug Administration (FDA) in 2018 as a first-line therapy for patients with EGFR mutation-positive metastatic non-small cell lung cancer. This marks another innovative breakthrough in the field of targeted therapy in the United States and provides more therapeutic tools for global EGFR treatment. Subsequently, Europe, Japan, China and other countries and regions also successively approved the drug for marketing.

In the Chinese market, this drug was introduced as "dacomitinib", and Pfizer still provides technical and supply support. After being registered with the National Medical Products Administration, the drug quickly entered the national medical insurance catalog, significantly reducing the patient's medication burden. Although research and development originated in the United States, its global promotion strategy has enabled it to be widely used in the Asia-Pacific region, including China. Especially among Chinese people with a high incidence of EGFR mutated lung cancer, its first-line treatment status has gradually been accepted by clinicians. The success of dacomitinib not only demonstrates the cutting-edge technology of American pharmaceutical companies in the field of precision tumor treatment, but also reflects the global trend of Sino-foreign cooperation to accelerate the benefits of new drugs to patients.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro